NGL Fine Chem Q1 FY27 results: board meet Aug 12

Key update: board meeting on August 12, 2026

NGL Fine Chem Ltd has scheduled a board meeting for Wednesday, August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The meeting is a standard compliance milestone for listed companies but is closely watched because it sets the tone for the start of FY27. The company operates in fine chemicals manufacturing and distribution, and it has recently reported a sharp improvement in full-year profitability. Investors typically track such board meetings not only for the headline numbers but also for updates on dividends, expansion plans, and business commentary, where available.

Trading window closure: timeline and compliance details

The company stated that the trading window has been closed from Wednesday, July 1, 2026, and will remain shut until Friday, August 14, 2026. The closure is linked to the results announcement and is intended to continue for 48 hours after the declaration of financial results. Such trading window restrictions are generally applied to designated persons and insiders to prevent trading while unpublished price sensitive information is in circulation. For market participants, the dates matter because they indicate when management is expected to finalise and publish the quarter’s numbers.

What will be approved: unaudited standalone and consolidated results

The August 12 board meeting is specifically for approving unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company has indicated that both standalone and consolidated results will be taken up. This matters because consolidated results capture performance across the group, while standalone results reflect the listed entity’s own books. Investors often compare both to understand contributions from subsidiaries or group structures, where applicable.

Where the stock is trading and listed peers

NGL Fine Chem was reported trading at ₹3,467.70 as of Thu Aug 06 2026 04:55:04. A separate reported snapshot places the share price at ₹3,447.7. The stock’s valuation metrics were also highlighted: NGL Fine Chem’s trailing twelve-month P/E ratio stands at 26.40 compared with the sector P/E of 32.37. In the same peer set, listed pharma and specialty peers cited include Sun Pharmaceutical Industries (0.41%), Divi's Laboratories (0.88%), and Torrent Pharmaceuticals (0.06%), as reported.

FY26 performance snapshot: revenue and profit growth

For FY26, NGL Fine-Chem Limited reported consolidated revenue of ₹500.95 crore and a consolidated net profit (PAT) of ₹48.13 crore. The net profit was reported as a 128% year-on-year increase from ₹21.12 crore in FY25. Revenue rose from ₹368.26 crore in FY25 to ₹500.95 crore in FY26, a growth rate reported at 36.03%. The combination of higher revenue and sharply higher PAT suggests improved operating leverage and/or margin expansion during FY26, based on the figures provided.

Latest quarterly trend: March 2026 quarter numbers

In the quarter ending March 2026, the company reported total revenue for the quarter of ₹151.69 crore and operating profit of ₹21.41 crore. Net profit for the quarter stood at ₹13.49 crore, with a QoQ change of -14.0% versus the December 2025 quarter and a YoY change of 2398.1% versus the March 2025 quarter (as reported). Adjusted EPS for the latest quarter was reported at ₹21.83, compared with ₹25.40 in the preceding quarter and ₹0.88 in the year-ago quarter. The company also reported that net profit jumped 2398.15% compared with the same period last year, while showing a -14.02% decline on a sequential basis.

Quarterly operating line items (reported series)

The company’s quarterly series (figures in ₹ crore) showed net sales rising from ₹93.02 crore in Mar 2025 to ₹144.75 crore in Mar 2026. Total expenditure increased over the same period from ₹89.11 crore to ₹127.15 crore. Operating profit moved from ₹3.91 crore (Mar 2025) to ₹17.6 crore (Mar 2026), with interim peaks shown in the period. Other income and interest costs were also listed in the quarterly table, indicating that non-operating items can meaningfully affect reported profitability in some quarters.

Dividend, AGM, and key shareholder dates

The board meeting held on May 21, 2026, included a recommendation of a final dividend of ₹1.75 per fully paid-up equity share, aggregating to ₹1.0812 crore (₹108.12 lakh). This final dividend is subject to shareholder approval at the company’s 45th Annual General Meeting scheduled for August 25, 2026. The record date for dividend entitlement is August 18, 2026. The register of members is stated to be closed from August 19 to August 25, 2026. The dividend was also described as translating to a dividend yield of 0.10%, based on the reported data.

Capacity expansion: Tarapur project investment and timeline

The company disclosed an investment of ₹182.75 crore in its Tarapur greenfield expansion project. Phase I is stated to be operational. Phase II is expected to start by the second half of FY27 (H2 FY27), with commercial production expected around that period, as reported. For investors tracking medium-term earnings capacity, the stated commissioning timeline is a key item to monitor alongside quarterly results and margin trends.

Governance and disclosures: encumbrance confirmation and results publication

The promoters confirmed that they did not create any encumbrance, directly or indirectly, on the shares held by them in the company during the financial year ended March 31, 2026. The company also noted newspaper advertisements of financial results for the quarter and year ended March 31, 2026, published in Free Press Journal (English) and Navshakti (Marathi) on Saturday, May 23, 2026. These disclosures are part of routine listed-company compliance and provide additional audit trail for investors.

Key dates and reference data (table)

Market impact and what investors will track next

Ahead of the August 12 meeting, the key market variable is the Q1 FY27 profit trajectory following the March 2026 quarter, where net profit was ₹13.49 crore. Valuation context is also in focus, with the company’s TTM P/E at 26.40 versus a sector P/E of 32.37, as cited. Investors will also watch for any commentary around the Tarapur expansion, particularly the stated Phase II start in H2 FY27 after an investment of ₹182.75 crore. Separately, the August calendar includes the dividend record date (August 18) and the AGM (August 25), where shareholders will vote on the final dividend proposal.